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Abstract: Bacillus Calmette–Guérin (BCG) vaccine is the only licensed vaccine against tuberculosis
(TB) in humans and animals. It is most commonly administered parenterally, but oral delivery is
highly advantageous for the immunisation of cattle and wildlife hosts of TB in particular. Since BCG
is susceptible to inactivation in the gut, vaccine formulations were prepared from suspensions of
Eudragit L100 copolymer powder and BCG in phosphate-buffered saline (PBS), containing Tween® 80,
with and without the addition of mannitol or trehalose. Samples were frozen at −20 ◦C, freeze-dried
and the lyophilised powders were compressed to produce BCG–Eudragit matrices. Production of the
dried powders resulted in a reduction in BCG viability. Substantial losses in viability occurred at the
initial formulation stage and at the stage of powder compaction. Data indicated that the Eudragit
matrix protected BCG against simulated gastric fluid (SGF). The matrices remained intact in SGF and
dissolved completely in simulated intestinal fluid (SIF) within three hours. The inclusion of mannitol
or trehalose in the matrix provided additional protection to BCG during freeze-drying. Control needs
to be exercised over BCG aggregation, freeze-drying and powder compaction conditions to minimise
physical damage of the bacterial cell wall and maximise the viability of oral BCG vaccines prepared
by dry powder compaction.
Keywords: BCG; Eudragit; oral vaccine; tuberculosis; in vitro viability
1. Introduction
According to the World Health Organisation (WHO) 2018 Global Tuberculosis (TB) Report,
TB remains one of the top 10 causes of death and the leading cause of morbidity from a single infectious
agent worldwide [1]. Similarly, livestock TB constitutes a major animal health problem. It has been
estimated that >50 million cattle are infected worldwide, costing US$3 billion annually due to reduced
cattle productivity, culling and movement and trade restrictions [2]. In addition, the global health
burden is increased by the fact that TB in animals is an important zoonosis, causing disease in humans,
particularly through the consumption of unpasteurised milk or by aerosol transfer from infected
animals. This factor prompted the WHO and allied organisations to publish a joint roadmap for
tackling zoonotic TB in 2017 [3].
Bacillus Calmette–Guérin (BCG) is a live bacterial vaccine that has been used in humans since
1921. The vaccine was registered for intramuscular administration to badgers in the UK in 2010, but is
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not currently registered for use in domestic livestock. BCG has been evaluated in numerous trials
and in many different species since its creation, and although efficacy can be variable, it is generally
considered an effective vaccine when administered parenterally [4]. However, the delivery of BCG to
mucosal surfaces through oral or intranasal administration is highly desirable in order to avoid the
use of needles for humans and domesticated animals and to simplify the immunisation of wildlife,
particularly through the presentation of BCG incorporated in bait [5].
The oral route is extensively used for drug delivery, even to exotic species [6], due to its ease
of administration and cost effectiveness. Oral vaccines have also been widely investigated, but the
difficulty of protecting protein and peptide antigens against degradation in the harsh conditions of the
gastrointestinal tract, notably the low pH and the presence of enzymes, remains a major obstacle to
progress in this area [7–9]. For BCG, data point to the need to protect the live vaccine against degradation
in the gut if it is to be effective when administered orally [10]. For example, in experimental studies
in humans, doses of oral BCG were administered either with 2% sodium bicarbonate (to neutralise
gastric acidity) immediately before [11] or simultaneously with the vaccine [12]. More convincingly,
the intra-gastric administration of BCG to brush-tailed possums (the principal wildlife reservoir of TB
in New Zealand) was less effective than vaccine administered by the same route in combination with
a drug to reduce gastric acidity or when administered intra-duodenally [13,14]. Protection of BCG
against degradation in the gut is also the basis of efforts to formulate BCG in alginate microspheres [15]
or in a lipid matrix for oral delivery to wildlife [16–18].
Many pharmaceutical oral dosage forms are enteric-coated with acid-resistant Eudragit®
copolymers to protect the stomach mucosa against irritation by drugs, including non-steroidal
anti-inflammatory drugs (NSAIDS), or to prevent the degradation of the active component upon
exposure to gastric acid or enzyme action [19,20]. The Eudragit® family of copolymers is based on
the anionic polymers of methacrylic acid and methacrylates. They contain –COOH as a functional
group and dissolve at specific pH values between 5.5 and 7.0, depending upon the grade. Furthermore,
these copolymers are available as powders, aqueous dispersions and in solution in inorganic solvents,
which renders them highly versatile for the formulation of drug delivery systems. Eudragit has
previously been employed for the encapsulation of protein antigens, including colonisation factor
antigen I and the F4 fimbriae antigen of Escherichia coli (ETEC) [21,22], with the latter being tested as an
oral tablet presentation for piglets. Metabolically active lactic acid bacteria have been incorporated in
enteric-coated tablets [23] and granules [24], and live-attenuated Ty21a Salmonella typhi have been
formulated as an oral vaccine in enteric-coated capsules [25]. Recently, a laminate presentation of
Bifidobacterium breve bacteria dried onto a Eudragit L100 film was shown to protect viable bacterial cells
from inactivation by simulated gastric fluid (SGF) [26].
The aim of the present study was to evaluate the potential of a BCG–Eudragit matrix formulation
for oral vaccination against TB, with a focus on the potential incorporation into bait for delivery
to badgers [5]. We used Eudragit L100 supplied in a powdered form. The polymer dissolves at a
pH above 6.0 and has been used as an enteric coating system for oral preparations relevant to this
study [21,22,26]. The protective capacity of the matrix formulation towards BCG was evaluated by the
exposure of samples to simulated gastric and intestinal fluids (SIF) and the assessment of the viability
of BCG was achieved by counting colony-forming units on solid agar medium.
2. Materials and Methods
2.1. Materials
BCG Pasteur strain (obtained originally from the Statens Serum Institute, Copenhagen, Denmark)
was grown in Middlebrook 7H9 liquid medium plus Albumin Dextrose Catalase (ADC) Supplement
(Beckton and Dickinson, UK) to a concentration of approximately 108 colony-forming units (cfu)/mL.
Aliquots were prepared and stored at −80 ◦C for subsequent experiments. Eudragit L100 polymer
(ratio of free carboxyl groups to ester groups approximately 1:1, MW 13.5 kDa) was provided by Röhm
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GmbH (Darmstadt, Germany). Polyoxyethylene-sorbitan monooleate (Tween® 80), mannitol and
trehalose were obtained from Sigma-Aldrich (Gillingham, UK).
2.2. Preparation of BCG-Loaded Eudragit® Matrices
Suspensions of Eudragit L100 powder in phosphate-buffered saline (PBS) (1.9 mL, 18% w/v) were
produced in glass vials with the addition of Tween® 80 (0.1% w/v) (formulation A). Separate formulations
contained, in addition, 0.2% w/v mannitol (formulation B) or 0.2% w/v trehalose (formulation C).
The Eudragit® aqueous dispersions were acidic and the pH was adjusted to 7.0 using 1 M NaOH
prior to sterilisation by autoclaving at 15 psi and 121 ◦C for 15 min. BCG Pasteur from stock (100 µL,
approximately 108 cfu/mL) was added to the sterile suspension and retained at −20 ◦C for 6 h prior
to freeze-drying (60 mbar (6000 Pa) pressure, −50 ◦C for 24 h (n = 3)) using an Edwards Modulyo
freeze-drier (Edwards, Burgess Hill, UK). Following freeze-drying, the powders were compressed
using a Specac KBr disc compressor (Specac, Orpington, UK) by applying a 4 ton load for 3 min,
to produce 13 mm diameter, 2.2 mm thickness BCG-loaded Eudragit matrices (Figure 1).
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Figure 1. Freeze-dried powders were compressed to produce Bacillus Calmette–Guérin (BCG)-loaded
Eudragit matrices with a diameter of 13 mm and a thickness of 2.2 mm.
2.3. BCG Viability during Matrix Formulation
Samples of formulation A were analysed for BCG viability during each stage of BCG–Eudragit
matrix production (formulation of suspensions, freezing at −20 ◦C, freeze-drying and powder
compaction). Samples of formulations B and C were analysed for BCG viability during all stages, except
after compaction. BCG was extracted from freeze-dried powders and solid matrices by resuspending in
10 mL PBS, pH 7.4 before dilution. Serial dilutio s of resuspended samples were made in sterile water
containing 0.05% Tween® 80. Aliq ots (100 µL) of each dilut on were spread onto Middlebrook 7H10
+ Oleic ADC (OADC) agar plates (n = 3, per dilution) and incubated at 37 ◦C for 21 days. The number
of cfu that resulted was counted for each dilution and converted to an average cfu.
2.4. BCG Viability Following Matrix Incubation in SGF and SIF
Individual BCG–Eudr git matrix samples (n = 3) were placed in SGF (10 mL HCl, 0.1 M, pH 1.2)
for 2 h at 37 ◦C in a water bath, rem v a d dried to constant weight at room temperature and then
transferred to SIF (10 mL HEPES, pH 7.4) and retained at 37 ◦C until they had fully dissolved. BCG was
extracted from matrices exposed to SGF by dissolving the matrix in 10 mL of HEPES solution (pH 7,
37 ◦C). Serial dilutions of BCG extracted from matrices incubated in SGF and SIF were made in sterile
water containing 0.05% Tween® 80. Aliquots (100 µL) of each dilution were spread onto Middlebrook
7H10 + OADC agar plates (n = 3 per dilution) and incubated at 37 ◦C for 21 days. The number of cfu
that resulted at each dilution was counted and converted to an average cfu.
2.5. Statistical Analysis
Analyses were performed using GraphPad Prism version 7.03 for Windows (GraphPad Software,
La Jolla, CA, USA, www.graphpad.com). Losses in BCG viability after each stage of formulation were
analysed by two-way ANOVA with Tukey’s multiple comparisons test against the log10 transformation
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of the raw data. The mean viability of BCG at each stage of evaluation was compared for differences
between the three formulations using the multiple t-test (with each stage of evaluation being analysed
separately to avoid assumptions about consistent standard deviations, using the raw data). Significant
p values were identified using the two-stage linear step-up procedure of Benjamini, Krieger and
Yekutieli to control the false discovery rate, with Q = 1%. Q is the proportion of false discoveries
allowed among the discoveries. Differences of p < 0.05 were considered significant throughout.
3. Results
The scanning electron micrographs in Figure 2 show the surface appearance of BCG-free matrices
produced by compaction of lyophilised powders prepared from dispersions of Eudragit powder in
PBS/Tween® 80 (formulation A) plus mannitol (formulation B) or trehalose (formulation C). Numerous
pores and fissures are apparent in the lower magnification image of formulation A and at higher
magnification for formulation C, compared with formulation B. The typical dense compact structure of
BCG-free matrices formed by the compaction of "as received" Eudragit L100 powder alone is shown in
Figure 2D. A more "open" morphology would be expected to facilitate the penetration of the BCG-loaded
Eudragit matrices by gastric fluids and the deactivation of exposed BCG. However, the presence of
PBS salts in the lyophilised powders was considered advantageous, since it provided the possibility of
local pH control within the porous matrices during transport through the stomach. Formulation A
BCG–Eudragit matrices retained an average of 88% of their initial weight after incubation in SGF for
2 h (216.3 ± SD 8.2 mg reduced to 190.6 ± SD 4.4 mg). When these matrix samples were subsequently
transferred from SGF to SIF, complete dissolution occurred within an average of 2.3 h (range, 125 to
150 min). The weight loss of formulations B and C in SGF and the time of dissolution in SIF were not
evaluated. However, our investigation of BCG viability following matrix incubation in SGF for 2 h and
incubation in SIF until the matrices dissolved revealed that formulations B and C behaved similarly to
formulation A, although specific measurements of time and weight were not recorded.
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(A) phos ate-buffered saline (PBS)/Tween® 80, (B) plus mannitol r (C) trehalose; (D) or produced by
the compaction of "as received" Eudragit L100 powder alone. The size-bar repres nts 10 µm.
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The concentration of the BCG stock solution after thawing was 1.48 × 108 (SD, 0.14 × 108) cfu/mL
and 100 µL was incorporated in each of the three types of matrix formulation. Table 1 shows the
impact on BCG viability caused by matrix formulation (freezing of BCG–Eudragit co-suspensions,
freeze-drying, dry powder compaction), and after the exposure of BCG–Eudragit matrices to SGF and
SIF. Figure 3 expresses the same data but illustrates the cumulative reduction in BCG viability for
each formulation.
Table 1. Viability of BCG (colony-forming units (cfu)) at each stage of matrix production (data represent
mean ± SD, n = 3). For each matrix, 100 µL of BCG stock (1.48 ± 0.14 × 108 cfu/mL) was used,
representing a starting BCG quantity of 1.5 × 107 cfu.
Matrix 1
Suspension
(pH 7)
Freezing
(−20 ◦C/6 h)
Freeze Drying
(24 h)
Dry Powder
Compaction
Matrix Exposure to
SGF and SIF
A 5.9 ± 0.4 × 105 5.5 ± 0.4 × 105 2.3 ± 0.7 × 105 2.0 ± 1.0 × 103 2.7 ± 0.1 × 103
B 6.1 ± 0.4 × 105 5.5 ± 1.1 × 105 7.0 ± 0.2 × 105 * ND 3.7 ± 0.3 × 103
C 6.5 ± 0.5 × 105 6.1 ± 0.5 × 105 6.5 ± 0.3 × 105 * ND 3.7 ± 0.2 × 103
1 BCG–Eudragit matrix composition: A, Eudragit L100/2 mL PBS/0.9 mL Tween® 80 (0.1% w/v); B, formulation A
plus mannitol (0.2% w/v); C, formulation A plus trehalose (0.2% w/v). * p < 0.05 for pair-wise comparisons against
matrix A.
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Figure 3. Cumulative reduction in BCG viability (cfu) for each matrix formulation (A, B, C) through each
stage. BCG–Eudragit matrix composition: (A) Eudragit L100/2 mL PBS/0.9 mL Tween® 80 (0.1% w/v);
(B) same as (A) plus mannitol (0.2% w/v); (C) same as (A) plus trehalose (0.2% w/v). * p < 0.05 for
pair-wise comparisons of matrices B and C against matrix A.
According to two-way ANOVA analysis of the log10-transformed data, significant losses in BCG
viability were apparently first encountered during the BCG–Eudragit powder suspension stage for all
formulations, with reductions of 1.36 to 1.40 log10 (Figure 3). No significant additional reduction in
viability was caused by freezing the suspensions at −20 ◦C for 6 h. Further reduction in BCG viability
was encountered after freeze-drying for matrix A, but not for matrices B and C, which included
mannitol and trehalose, respectively. Thus, upon completion of the freeze-drying stage there was
significant retention of BCG viability for matrices B and C compared with A (Table 1, Figure 3).
Freeze-dried formulations were compressed to form matrices and then incubated in SGF, followed by
SIF. All formulations converged on an incremental loss of BCG viability to around 3.4 × 103 cfu (Table 1),
representing a total cumulative average loss in BCG viability of 3.65 log10 (range, 3.61–3.74 log10).
For formulation A, we additionally assessed the impact of compaction on BCG viability. Compaction
alone caused a significant, 100-fold reduction in apparent BCG viability compared with the viable
concentration of BCG after freeze-drying (Figure 3). It is noteworthy for this formulation that the
exposure of BCG–Eudragit matrices to SGF/SIF caused no further reduction in viability, despite their
apparently porous morphology (Figure 2), indicating the protective effect of this matrix against low
pH conditions. As we did not assess the effect on BCG of compaction of the formulations containing
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mannitol (B) or trehalose (C), we cannot be sure that the impact of powder compaction on these
formulations was equivalent to formulation A.
4. Discussion
BCG-containing Eudragit matrices were formulated using a dry powder compaction approach
in an effort to produce an oral BCG vaccine that retains high viability during transit through the gut.
The matrices were physically stable for 2 h at low pH (in SGF) and the data indicate that at least
the matrix produced from PBS/Tween® 80 did not appreciably permit the low pH medium (SGF) to
penetrate, causing loss in BCG viability. Although we did not include a control of BCG incubated in
SGF alone, Dobakhti et al. [15] incubated BCG for 1.5 h in SGF at the same pH (1.2) and found the
viability was reduced by approximately 1 log10. Therefore, our incorporation of BCG in a Eudragit
matrix had the desired effect of protecting BCG from the detrimental action of low pH. Although we
cannot say with certainty this was the case for the matrices containing mannitol or trehalose, it seems
probable. Despite this encouraging result, we encountered a total cumulative average loss in apparent
BCG viability from start to finish of 3.65 log10. Analysis of the data show that significant losses occurred
at the initial formulation stage and at the stage of compaction.
BCG has a tendency to aggregate [27], leading to the apparent effect of reducing the cfu count,
which is interpreted as a loss in viability. For this reason, all BCG–Eudragit matrix formulations
included Tween® 80, which is commonly added to BCG suspensions prior to culture or vaccine
formulation to prevent aggregation [28–30]. Despite this, we think aggregation was the most likely
explanation for the apparent loss in BCG viability during the initial formulation stage from 1.5 × 107
cfu to an average of 6.2 × 105 cfu across the three formulations; indeed, aggregates of BCG were seen
in the initial formulations under the light microscope (data not shown). Bacterial death at this point
seems unlikely since the suspensions were adjusted to pH 7.0 before adding BCG.
A decided disadvantage of the dry powder compaction approach described here for the production
of oral BCG vaccine relates to the reduction of BCG viability following powder compaction (evident for
formulation A). The application of pressure (e.g., French Press) is recognised as a highly efficient way
to disrupt the cell wall of mycobacteria [31]. The pressure normally applied (approximately 100 MPa)
is around three times lower than the pressure used to produce the BCG–Eudragit matrices (290 MPa)
in the present study. By contrast, a pressure of 5 MPa did not reduce the viability of live bacteria in
the tablets produced from hydroxypropyl methylcellulose acetate succinate (HPMCAS) [23]. Thus,
the approach of formulating live BCG vaccines by dry powder compaction appears to be severely
limited by the sensitivity of the bacteria to compaction. Attempts to reduce the duration and pressure
of compaction resulted in matrices that were unstable in SGF (data not shown), suggesting that the
inclusion of a binder (e.g., HPMCAS) would be beneficial in future formulations.
We did not investigate the loss of cfu of BCG in formulations B and C during compaction alone,
although we show that the cfu of BCG in formulations B and C strongly decreased during two combined
steps, i.e., compression and SGF and SIF incubation. Compared to formulation A, formulations B
and C contained additional mannitol and trehalose, respectively. However, the ratio of Eudragit to
mannitol and trehalose is very high, i.e., 18:0.2 (w/w). Consequently, we neither expect a major positive
or negative effect of mannitol and trehalose on the loss of cfu during compaction, nor dramatic weight
loss in SGF.
Gheorghiu et al. [29] reported that freeze-drying results in loss of viability of BCG Pasteur and
this was also our observation for matrix A. Loss in BCG viability during freezing, due to ice crystal
formation and/or salt crystal growth (arising from the use of PBS as the suspension medium), may have
contributed to the rupture of the bacteria cell wall. The addition of mannitol or trehalose provided
protection to BCG during freeze-drying, as expected from the literature. Mannitol is widely used as a
cryo-protectant to improve the viability of lyophilised formulations and has been considered for the
formulation of new, recombinant BCG vaccines for TB [32]. Similarly, the inclusion of trehalose is a
common means of stabilising biomacromolecules during drying [33].
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The key finding from this study is that formulations of BCG–Eudragit L100 matrices using dry
powder compaction resulted in a significant reduction in viability from the start of formulation to final
exposure to SGF/SIF, regardless of the formulation used. Although the minimum efficacious dose for
oral BCG has not been determined for any species, typical efficacious doses in experimental studies
in humans [12] and animals (reviewed in [4]) exceed 107 cfu. It therefore seems unlikely that the
present approach of dry powder compaction would produce an efficacious oral vaccine. Nevertheless,
the extensive application of Eudragit® for oral drug delivery recommends further studies to exploit
the advantages of this material for the production of oral BCG vaccines. Possible strategies include the
incorporation of a binder with the dry powders, in order to reduce the compaction forces required for
matrix production and thus minimise the physical damage to the bacterial cell walls, and sonication to
disperse aggregates of BCG before freezing.
5. Conclusions
BCG–Eudragit L100 matrices were produced by dry powder compaction to investigate their
potential as oral vaccines for animals. The production of BCG–Eudragit dry powders resulted in
significant loss of apparent viability of BCG. Matrix production by powder compaction resulted in a
further reduction in BCG viability of around 100-fold. However, the incubation of at least one of the
matrices in SGF followed by SIF showed no further reduction in viability, indicating the capacity of the
matrices to control SGF ingress and protect the residual live bacteria.
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